Citi Upgrades Ultragenyx Pharma (RARE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $16.17 -3.64%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 43 | New: 8
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 43 | New: 8
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz upgraded Ultragenyx Pharma (NASDAQ: RARE) from Sell to Neutral with a price target of $54.00 (from $46.00).
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $53.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amrize Ltd (AMRZ) PT Raised to $43 at DA Davidson
- Reddit (RDDT) PT Lowered to $120 at Cantor Fitzgerald
- Canada Packers Inc (CPKR:CN) PT Lowered to Cdn$14 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
